# Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis

> **NCT02090413** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 241 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **DRUG:** dimethyl fumarate
- **DRUG:** acetylsalicylic acid
- **DRUG:** ASA-Placebo

## Key facts

- **NCT ID:** NCT02090413
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-11
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2016-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090413, "Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02090413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*